Pulse PubMed Daily Digest — 2026-08-10
Pipeline run: attempt 1 of 3 | Status: complete
Date window: CRDT 2026-08-09 → 2026-08-10 (T3 expanded to 48h: 2026-08-08)
Articles reviewed: 69 total across 10 watchlist topics
HIGH priority: 20 | STANDARD: 25 | REVIEW_LATER: 14 | FILTERED: 10
🔴 HIGH PRIORITY (score ≥ 7)
T7 Cardiometabolic / Sentinel
1. [score 9] Tirzepatide predicted 10-year CVD risk reduction over 3 years in obesity — Eur J Prev Cardiol (2026-08-10)
PMID: 42572119 | DOI: 10.1093/eurjpc/zwag408
Sattar N, Mamas M, Li R, et al. (Eli Lilly)
Post hoc of SURMOUNT-1 phase 3 RCT (962 pts, 176 weeks): tirzepatide 15 mg → predicted 10-yr CVD absolute risk reduction –1.31% vs. placebo increase +3.84% (HR=0.62, p<0.001). FHS risk equation predictability validated vs. REWIND (HR 0.83 observed vs. 0.85 predicted). Pending confirmation in SURMOUNT-MMO.
2. [score 8] CKD prevalence rising despite declining incidence in Danish T1D/T2D nationwide registry 2016–2024 — Diabetes Obes Metab (2026-08-09)
PMID: 42571988 | DOI: 10.1111/dom.71188
Lee CJ, Gerds TA, Rossing P, et al. (Steno Diabetes Center Copenhagen)
Nationwide registry: CKD prevalence rose 24.8→37.3% in T2D over 8 years while incidence fell 55.3→43.7/1000 PY. Mortality among those with CKD remained substantially elevated despite improved cardiometabolic therapies.
3. [score 8] Non-invasive MASH/fibrosis detection via LIID ultrasound score + LSM, multicenter 410 pts — J Gastroenterol Hepatol (2026-08-09)
PMID: 42572009 | DOI: 10.1111/jgh.70553
Gao F, Zheng MH, Wei L, et al. (10 Chinese hospitals)
LIID score AUROC 0.71 for MASH (rule-out sens 89.6%, threshold 6.0; rule-in spec 88.4%, threshold 7.8); LSM AUROC 0.86 for advanced fibrosis. Non-invasive dual-biomarker strategy reduces need for liver biopsy in MASLD clinical practice and trials.
4. [score 7] GLP-1RA not associated with increased bowel obstruction/ileus risk — 298k nationwide database study — Diabetes Obes Metab (2026-08-09)
PMID: 42572004 | DOI: 10.1111/dom.71189
Matsuo Y, Okada A, Yasunaga H (Tokyo)
Active-comparator new-user design vs. SGLT2i (n=298,124): no significant difference in bowel obstruction/ileus risk (HR 0.80; 95% CI 0.52–1.24). Definitively addresses major GLP-1RA safety concern with large nationwide evidence.
5. [score 7] CV risk prediction models need recalibration in Chinese populations — Diabetes Obes Metab (2026-08-09)
PMID: 42571983 | DOI: 10.1111/dom.71212
Fan X, Tao R, et al. (57,062 Chinese participants in 2 cohorts)
Five CVD risk models showed acceptable discrimination (C-statistic 0.58–0.78) but substantial miscalibration; systematic overprediction in general population (E/O 1.47–3.78). Recalibration essential before threshold-based clinical use in China.
6. [score 7] HCM variant reclassification changes 22% of variants, improves risk discrimination — Int J Cardiol (2026-08-09)
PMID: 42571822 | DOI: 10.1016/j.ijcard.2026.134718
Del Franco A, Olivotto I, Girolami F, et al. (Careggi, Florence; 805 probands)
22.1% of 276 HCM variants reclassified: 5.5% P/LP downgraded, 18.3% VUS upgraded; reclassification improved HR for all-cause death and ventricular arrhythmia. Supports systematic periodic variant review in HCM genomics.
7. [score 7] Barth syndrome heart transplantation outcomes — single-center + literature review — Transplant Proc (2026-08-09)
PMID: 42571938 | DOI: 10.1016/j.transproceed.2026.07.013
Ragozzino JRM, Azeka E et al. (Brazil)
Institutional experience + systematic literature review for Barth syndrome (X-linked tafazzin-mutation cardiomyopathy) referral to heart transplantation. High unmet need, first published from this Brazilian center.
T8 Aging / Population Health
8. [score 9] Social isolation + loneliness → frailty mediates 55% of loneliness-mortality association, 31 countries — Age Ageing (2026-08-03)
PMID: 42572000 | DOI: 10.1093/ageing/afag234
Miao Y, Wu J et al. (80,050 participants, 4 cohorts, 31 countries)
Social isolation (pooled HR=1.33) and loneliness (HR=1.25) predict all-cause death; frailty mediates 24% of social isolation–mortality and 55% of loneliness–mortality association. Establishes frailty as a key modifiable target for aging public health interventions.
T1 Hematologic Malignancies
9. [score 8] MDS/MPN response criteria systematic review + meta-analysis — international expert consortium — Blood Neoplasia (2026-08-01)
PMID: 42571225 | DOI: 10.1016/j.bneo.2026.100266 | Open access
Hunter AM, Tremblay D, Savona MR, et al. (19 authors, MDS/MPN International Working Group)
First comprehensive systematic review + meta-analysis establishing evidence base for standardized response criteria across MDS/MPN overlap syndromes. Critical for clinical trial design in this rare hematologic malignancy cluster.
10. [score 8] Clonal dynamics in MBL/MGUS/CH — precision prevention framework from Moffitt/Dana-Farber/Mayo — Semin Cancer Biol (2026-08-09)
PMID: 42571831 | DOI: 10.1016/j.semcancer.2026.102615
Xiao Z, Sekar A, Ghia P, Kumar S, Parikh SA
Proposes unified "precision prevention" paradigm for intercepting high-risk clonal trajectories in MBL, MGUS, and CH. Identifies aging-associated inflammation and feed-forward microenvironmental loops as universal drivers. Highly relevant to early hematologic malignancy interception strategies.
11. [score 8] 10-color flow cytometry vs. NGS MRD in B-ALL — multicenter prospective, TALWG — Int J Lab Hematol (2026-08-09)
PMID: 42571922 | DOI: 10.1111/ijlh.70216
Chanswangphuwana C, Polprasert C et al. (51 pts, 8 Thai centers)
FC MRD positivity at 3 months: HR 3.81 for inferior RFS. FC/NGS concordance 80.7%. Validates 10-color FC as resource-accessible MRD platform; directly applicable in clinical hematology programs with limited NGS access.
12. [score 8] PET/CT-adapted ABVD for Hodgkin lymphoma — 10-year follow-up of 563 patients (GATLA LH-05) — Br J Haematol (2026-08-09)
PMID: 42571952 | DOI: 10.1111/bjh.70721
Pavlovsky A, Pavlovsky S et al. (563 pts, Argentina, median 93.5 months)
10-year PFS 76.2%, OS 93.7%; PET3 strongest independent predictor of PFS; disease stage not independently prognostic. Definitive long-term evidence supporting PET-guided treatment discontinuation in PET3-negative cHL across all stages.
13. [score 7] Liver enzyme patterns independent prognostic markers in CLL — nationwide 3,448 pts — Leuk Lymphoma (2026-08-09)
PMID: 42571701 | DOI: 10.1080/10428194.2026.2711592
Bronstein Y, Nachmias N et al. (Clalit Health Services, Israel)
Cholestatic elevation (ALP/GGT) → inferior OS (HR 1.21, p=0.008) and higher infection hospitalization rates. Simple routinely available baseline lab marker for CLL risk stratification.
T3 Early Cancer Detection
14. [score 8] ctDNA in GI cancers — synthesis of DYNAMIC, CIRCULATE, COBRA, and COBRA trials — EClinicalMedicine (2026-08-01)
PMID: 42571422 | DOI: 10.1016/j.eclinm.2026.104122 | Open access
Mukherjee S, Ahluwalia MS et al. (Miami Cancer Institute)
ctDNA strongly prognostic but not yet treatment-selecting in most GI cancer contexts; de-escalation supported in ctDNA-negative stage II CRC (DYNAMIC), but escalation did not improve stage III outcomes (DYNAMIC-III). Definitive state-of-field synthesis for clinical decision-making.
15. [score 8] Exosome-based liquid biopsy in biliary tract cancer — nanotechnology platforms + AI — Int J Nanomedicine (2026-08-03, CRDT 2026-08-08)
PMID: 42569449 | DOI: 10.2147/IJN.S613686 | Open access
Choi Y, Choi J et al. (Chung-Ang University, Korea)
Comprehensive review of nanoVelcro chips, SERS biosensors, CRISPR-Cas nanosensors, and AI-driven exosomal signature interpretation for early BTC detection. BTC has near-zero early detection rate currently; this platform convergence is a key development signal.
T4 AI/ML Clinical Diagnostics
16. [score 8] AI ECHO INSIGHT — first prospective blinded RCT design for AI echocardiogram interpretation — Contemp Clin Trials (2026-08-09)
PMID: 42571809 | DOI: 10.1016/j.cct.2026.108431
Lee KK, Ouyang D, He B et al. (Kaiser Permanente Northern California)
1,200 TTE studies, 3-arm blinded randomized trial. Primary endpoint: rate of substantial change in preliminary vs. final reports (AI-assisted vs. human-assisted workflows). NCT07229300. Addresses scalability crisis in 30M+ annual TTEs.
17. [score 7] ABUS + AI CAD achieves 95% sensitivity for BIRADS 3-4 breast lesions — J Ultrasound (2026-08-09)
PMID: 42572099 | DOI: 10.1007/s40477-026-01212-1
Moschetta M et al. (Bari, Italy; n=54 patients)
AI-CAD on ABUS: SE 95%, SP 79%, AC 88%, NPV 92% for BIRADS 3-4 lesions vs. CNB histology. Demonstrates potential to reduce unnecessary biopsies in challenging breast lesion category.
T5 Precision Oncology
18. [score 8] p16/Ki-67 dual-stain — systematic review + meta-analysis for CIN2+/CIN3+ in HPV+ women (n=24,519) — Eur J Obstet Gynecol Reprod Biol (2026-08-07)
PMID: 42571742 | DOI: 10.1016/j.ejogrb.2026.115354
Muhaisen AHM et al. (Yarmouk University, Jordan; 27 studies)
CIN2+ sensitivity 0.837, specificity 0.643, AUC 0.826; CIN3+ sensitivity 0.862, AUC 0.830. More sensitive than cytology for CIN3+. Supports p16/Ki-67 as reflex triage test in HPV-based screening; GRADE certainty very low.
T6 Novel Therapeutics
19. [score 8] Baseline IL-6 independently predicts severe irAEs AND inferior survival in gastric cancer ICI — Gastric Cancer (2026-08-09)
PMID: 42572075 | DOI: 10.1007/s10120-026-01744-9
Liu W, Zhao L et al. (PUMCH Beijing; n=244)
IL-6 predicts high-grade irAEs (OR=2.74) and inferior OS, confirmed by PSM. Mediation analysis shows irAEs do not explain the IL-6-survival relationship — IL-6 reflects adverse inflammatory baseline state. Actionable pre-treatment biomarker for ICI risk stratification in GC.
20. [score 7] KRAS inhibition resistance — comprehensive mechanistic review of adaptive tumor evolution — J Adv Res (2026-08-09)
PMID: 42571850 | DOI: 10.1016/j.jare.2026.08.030
Salih R, Rahmani M et al. (Khalifa University)
Synthesizes resistance to KRAS G12C/G12D/pan-RAS inhibitors via on-target alterations, bypass pathway rewiring, and non-genetic cell state changes. Evaluates rational combinations, PROTACs, and KRAS immunotherapy as next-generation strategies.
🟡 STANDARD PRIORITY (score 5–6) — Selected Highlights
| PMID | Score | Topic | Title (brief) |
|---|---|---|---|
| 42571998 | 6 | T1/T6 | Rituximab-CD20+ EV immune complexes reverse NK cell suppression in B-NHL (J Extracell Vesicles) |
| 42571919 | 6 | T1 | SPCs in LPL/WM — MDS borderline excess risk, 521 pts (Br J Haematol) |
| 42571242 | 6 | T1/T5 | CARD11 mutation strength determines BTK inhibitor sensitivity in ABC-DLBCL (Blood Neoplasia) |
| 42572075 | 6 | T6 | Lysosome-targeted ammonia nanogenerator potentiates HCC immunotherapy (Adv Mater) |
| 42571484 | 6 | T6 | Racial/socioeconomic disparities in ICI use for stage III NSCLC post-CRT (ESMO Real World Data) |
| 42571860 | 6 | T6/T9 | Chordoma molecular landscape: Brachyury targeting, CAR-T, AI segmentation review (BBA Rev Cancer) |
| 42571423 | 6 | T4 | Digital pathology AI for MASH fibrosis in drug trials — needs, progress, barriers (J Clin Exp Hepatol) |
| 42571252 | 6 | T4 | Morphometric breast tissue malignantization algorithm: AUC 0.974 (Cancer Inform) |
| 42571185 | 6 | T4 | LLM (GPT-4o, DeepSeek-R1) vs. TB physicians in post-discharge care: LLMs outperform in patient education (Digit Health) |
| 42571955 | 6 | T5 | Spatiotemporal oncomiRNA heterogeneity + AI for precision theranostics (Cancer Rep) |
| 42571761 | 6 | T6 | DECT baseline iodine uptake predicts PFS in ICI-treated metastatic melanoma (Eur J Radiol) |
| 42571170 | 6 | T6 | High-titer ANA → 8× irAE risk in advanced GC ICI (OR=7.98; n=244) (Ther Adv Med Oncol) |
| 42571219 | 6 | T6 | TORCH-LE trial: SCRT + CapeOx + PD-1 for organ preservation in high-risk early rectal cancer (phase II protocol) |
| 42571904 | 6 | T8 | Strength exercise HR=0.26 for dementia risk in prospective study of 5,074 older Japanese adults |
| 42572043 | 5 | T7 | Urinary biomarkers in HF management: urine albumin/sodium useful; other biomarkers insufficient evidence (review) |
| 42572096 | 5 | T8 | eGFR independently predicts frailty, sarcopenia, impaired gait in 1,346 older adults |
| 42571032 | 5 | T1 | T/NK lymphoma Saudi Arabia: 5-yr OS 56%; LDH+ECOG+renal insufficiency predict inferior survival (n=89) |
| 42571079 | 5 | T4 | AI + clinical guideline adherence: only 6 empirical studies; evidence sparse (structured narrative review) |
| 42571830 | 5 | T5/T6 | CAR-T atlas in lung cancer: bibliometric analysis 2016–2025 (Pharmacol Res) |
| 42571038 | 5 | T5 | Lung cancer in Saudi never-smokers: 36%, EGFR 39.5%, ALK 20% — supports universal molecular testing |
| 42571652 | 5 | T6/T7 | HF ↔ Cancer bidirectional links: CHIP as novel link, disparities in cardio-oncology (Heart) |
| 42572067 | 5 | T5/Sentinel | Novel MPO inhibitor BTB11556 (IC50 12.5 µM in Kasumi-1 AML cells) via QSAR-pharmacophore screening |
| 42572046 | 5 | Sentinel | Anti-Scl-70 positivity → subclinical diastolic dysfunction without overt systemic sclerosis (n=486) |
📋 Coverage Summary by Topic
| Topic | Candidates | HIGH | Status |
|---|---|---|---|
| T1 Hematologic Malignancies | 13 | 5 | Normal |
| T2 CBC + ML Hematology | 0 | 0 | ⚠️ Zero results (both primary + fallback queries) |
| T3 Early Cancer Detection | 1 | 1 | ⚠️ Sparse (1-day = 0; expanded to 48h = 1 result) |
| T4 AI/ML Clinical Diagnostics | 12 | 2 | Normal |
| T5 Precision Oncology | 5 | 2 | Normal |
| T6 Novel Therapeutics | 13 | 2 | Normal |
| T7 Cardiovascular-Metabolic | 15 (capped) | 7 | Normal (47 total) |
| T8 Aging / Longevity | 4 | 1 | Normal |
| T9 Rare Diseases | 1 | 0 | ⚠️ 1 FP only; 42571938 (Barth syndrome) found via T7 |
| Sentinel | 10 (capped) | 3 | Normal |
T2 note: No CBC/ML hematology articles indexed in 1-day CRDT window with both primary and fallback queries. Sparse day.
T3 note: Expanded to 48h window (2026-08-08 to 2026-08-10) found PMID 42569449 (exosome liquid biopsy, BTC). Also PMID 42571422 (ctDNA GI cancers) found via T5 and cross-tagged to T3.
T9 note: 42571650 (SCD meta-analysis) is a false positive. 42571938 (Barth syndrome) found via T7 cardiometabolic search, tagged T9.
🔎 Notable Cross-Topic Signals
IL-6 + ANA as dual ICI toxicity biomarkers in gastric cancer (PMIDs 42572075, 42571170): Same PUMCH group publishes companion papers showing baseline IL-6 and high-titer ANA are independent, complementary biomarkers for severe irAE prediction. Together they suggest a practical pre-treatment autoimmunity profiling approach for GC ICI candidates.
GLP-1RA safety + efficacy convergence in T7 (PMIDs 42572119, 42572004): Tirzepatide demonstrates durable 3-year CVD risk reduction (42572119) while GLP-1RA safety concern (bowel obstruction) is definitively addressed (42572004). Both in Diabetes Obes Metab, same date.
MDS/MPN triage triple (PMID 42571225): International systematic review on response criteria is complemented by the clonal dynamics precision prevention framework (42571831) — together they set the stage for a new generation of MDS/MPN clinical trials with standardized endpoints and better patient selection.
Generated by Pulse PubMed pipeline — attempt 1/3 — 2026-08-10T09:33:32Z